Sarepta Therapeutics, Inc. SRPT today announced that the U.S. Food and Drug
Administration's (FDA) Peripheral and Central Nervous System Advisory
Committee meeting scheduled for Friday, January 22 has been postponed by
the FDA due to an anticipated severe winter snowstorm forecasted to hit
the Washington D.C. area. A future meeting date will be announced in the
Federal Register. In the event of a change in the February 26, 2016
PDUFA date, the company will provide an update at that time.
The Advisory Committee was scheduled to review Sarepta's New Drug
Application (NDA) for eteplirsen, for the treatment of Duchenne muscular
dystrophy (DMD) amenable to exon 51 skipping. The new drug application
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in